Fig.
2. Tumorigenicity of CDDP-resistant EAC cells vs. parent EAC
cells. A. The tumor growth progress displaying the
differential tumorigenicity between the resistant and sensitive EAC
cells. B. Two-way ANOVA analysis was done for tumor size on day
17. Data are expressed as mean ± SD. * p < 0.05, **p < 0.01, *** p < 0.001, ns:
nonsignificant. EAC: Ehrlich ascites carcinoma, SEC: solid Ehrlich
carcinoma, SEC-CDDP: SEC treated with cisplatin, SEC-indomethacin: SEC
treated with indomethacin, SEC-combination: SEC treated with CDDP and
indomethacin, SEC/CDDP: cisplatin-resistant SEC, SEC/CDDP-CDDP:
cisplatin-resistant SEC treated with cisplatin, SEC/CDDP-indomethacin:
cisplatin-resistant SEC treated with indomethacin, SEC/CDDP-combination:
cisplatin-resistant SEC treated with CDDP and indomethacin.